Several companies have MC4R agonists that are being investigated in the treatment of obesity, including piperazinebenzylamines, piperazinethylamines, piperazinesulfonamides and other small-molecule agonists [25]. This evidence concerns the gene MC4R and obesity due to melanocortin 4 receptor deficiency.